Important Notice and Financial Summary Key Financial Data and Indicators In Q1 2022, the company's operating revenue increased by 23.79% year-on-year, but net profit attributable to shareholders significantly decreased by 37.17%, with net cash flow from operating activities also down 71.36% Key Financial Performance Indicators | Indicator | Q1 2022 | YoY Change (%) | | :--- | :--- | :--- | | Operating Revenue | 473,617,820.88 Yuan | 23.79% | | Net Profit Attributable to Shareholders of the Listed Company | 60,941,331.70 Yuan | -37.17% | | Net Profit Attributable to Shareholders of the Listed Company, Excluding Non-Recurring Gains and Losses | 59,082,562.55 Yuan | -36.48% | | Net Cash Flow from Operating Activities | 4,470,962.15 Yuan | -71.36% | | Basic Earnings Per Share (Yuan/share) | 0.35 Yuan | -36.36% | | Weighted Average Return on Net Assets (%) | 1.08% | Decrease of 0.67 percentage points | Key Financial Position Indicators | Indicator | March 31, 2022 | Change from End of Previous Year (%) | | :--- | :--- | :--- | | Total Assets | 6,854,436,764.22 Yuan | -1.38% | | Total Equity Attributable to Shareholders of the Listed Company | 5,616,540,791.70 Yuan | -1.70% | Non-Recurring Gains and Losses Items During the reporting period, total non-recurring gains and losses amounted to approximately 1.86 million Yuan, primarily from government grants and fair value changes of financial assets Non-Recurring Gains and Losses Details | Item | Amount (Yuan) | | :--- | :--- | | Gains/Losses on Disposal of Non-Current Assets | 56,003.42 | | Government Grants Included in Current Profit/Loss | 1,774,258.81 | | Gains/Losses from Fair Value Changes of Financial Assets Held for Trading | 596,220.58 | | Other Non-Operating Income and Expenses | 188,528.68 | | Less: Income Tax Impact | 144,781.29 | | Less: Impact on Minority Interests (After Tax) | 611,461.05 | | Total | 1,858,769.15 | Analysis of Changes in Key Financial Indicators The significant decline in net profit and EPS is primarily due to reduced investment-related income, while decreased operating cash flow resulted from increased employee compensation and raw material procurement - Net profit attributable to shareholders and non-recurring net profit both decreased by over 36% year-on-year, mainly because the previous year recognized deemed disposal gains from associates and received investment dividends, which were not received in the current reporting period6 - Net cash flow from operating activities decreased by 71.36% year-on-year, primarily due to increased payment of wages and bonuses payable from the end of the previous year, and increased procurement payments for raw material stocking to address supply chain challenges6 Shareholder Information Total Number of Shareholders and Shareholding of Top Ten Shareholders As of the reporting period end, the company had 11,295 common shareholders, with controlling shareholder Mr. Jiang Wei and his spouse Ms. You Jie holding 41.66% combined, and HKSCC NOMINEES LIMITED as the second largest shareholder - As of the end of the reporting period, the company had 11,295 common shareholders7 Top Ten Shareholders' Shareholding | Shareholder Name | Shareholding Percentage (%) | Number of Shares Held (shares) | Nature of Shares | | :--- | :--- | :--- | :--- | | Jiang Wei | 25.28 | 44,449,000 | Domestic Natural Person | | HKSCC NOMINEES LIMITED | 21.58 | 37,948,789 | Other | | You Jie | 16.38 | 28,800,000 | Domestic Natural Person | | Lou Guoliang | 4.05 | 7,125,075 | Overseas Natural Person | | Shanghai Zhanze Enterprise Management Partnership (Limited Partnership) | 3.68 | 6,471,000 | Domestic Non-State-Owned Legal Person | - Among the top ten shareholders, Jiang Wei and You Jie are spouses and are the company's controlling shareholder and actual controller. Shanghai Zhanze Enterprise Management Partnership (Limited Partnership) is an enterprise controlled by Jiang Wei1011 Financial Statements Consolidated Balance Sheet As of March 31, 2022, total assets were 6.85 billion Yuan, a slight decrease of 1.38% from year-end, with cash decreasing while inventory and accounts receivable increased. Total liabilities decreased to 835.47 million Yuan Key Asset Items | Key Asset Item | March 31, 2022 (Yuan) | December 31, 2021 (Yuan) | | :--- | :--- | :--- | | Cash and Cash Equivalents | 2,697,254,015.40 | 2,901,402,136.28 | | Accounts Receivable | 399,705,182.28 | 370,503,253.97 | | Inventories | 376,825,300.32 | 354,765,098.16 | | Total Assets | 6,854,436,764.22 | 6,950,355,416.19 | Key Liabilities and Equity Items | Key Liabilities and Equity Item | March 31, 2022 (Yuan) | December 31, 2021 (Yuan) | | :--- | :--- | :--- | | Short-Term Borrowings | 2,000,000.00 | 25,184,398.63 | | Employee Benefits Payable | 53,724,654.27 | 78,697,949.25 | | Total Liabilities | 835,467,406.99 | 890,070,458.09 | | Total Equity Attributable to Parent Company Shareholders | 5,616,540,791.70 | 5,713,459,639.49 | Consolidated Income Statement Q1 2022 operating revenue grew 23.79% to 473.62 million Yuan, but significant increases in operating costs, selling, and administrative expenses, coupled with an 83.17% drop in investment income, led to a 37.17% decline in net profit Consolidated Income Statement Highlights | Item | Q1 2022 (Yuan) | Q1 2021 (Yuan) | YoY Change | | :--- | :--- | :--- | :--- | | Total Operating Revenue | 473,617,820.88 | 382,585,206.31 | +23.79% | | Operating Cost | 156,221,109.72 | 96,511,274.44 | +61.87% | | Selling Expenses | 148,064,767.78 | 122,111,278.28 | +21.25% | | Administrative Expenses | 75,239,783.34 | 49,667,248.47 | +51.49% | | Research and Development Expenses | 45,520,090.97 | 36,527,079.45 | +24.62% | | Investment Income | 2,313,643.50 | 13,750,368.57 | -83.17% | | Operating Profit | 69,617,649.65 | 114,812,074.20 | -39.36% | | Net Profit Attributable to Parent Company Shareholders | 60,941,331.70 | 96,992,749.11 | -37.17% | Consolidated Cash Flow Statement Net cash flow from operating activities significantly decreased to 4.47 million Yuan due to increased payments for goods and employee compensation, while investing and financing activities also resulted in net outflows, leading to a lower period-end cash balance Consolidated Cash Flow Statement Highlights | Item | Q1 2022 (Yuan) | Q1 2021 (Yuan) | | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 4,470,962.15 | 15,609,445.06 | | Net Cash Flow from Investing Activities | -174,414,144.19 | -717,296,418.52 | | Net Cash Flow from Financing Activities | -121,583,632.57 | -1,377,033.95 | | Effect of Exchange Rate Changes on Cash | -3,965,472.94 | 1,826,678.69 | | Net Increase in Cash and Cash Equivalents | -295,492,287.55 | -701,237,328.72 | | Cash and Cash Equivalents at Beginning of Period | 1,283,892,952.34 | 1,327,887,460.94 | | Cash and Cash Equivalents at End of Period | 988,400,664.79 | 626,650,132.22 |
昊海生物科技(06826) - 2022 Q1 - 季度财报